ZTlido, a lidocaine patch 1.8% developed by Scilex Pharmaceuticals, a Sorrento Therapeutics subsidiary, is attempting to redefine this type of nonopioid treatment for patients with postherpetic neuralgia.
Howard Fillit, MD, the founding executive director and chief scientific officer of the Alzheimer’s Drug Discovery Foundation, sat with MD Magazine to discuss the state of therapies for Alzheimer disease (AD), including funding-related struggles and the burden faced by physicians who treat patients with AD.
The hottest subject in psychiatry right now is the clinical use of an old anesthetic (and sometimes party drug), ketamine, as the most rapidly acting and effective antidepressant the field has ever seen.
Underscoring a commitment to make health care accessible to all populations, the Kraft Center for Community Health at Massachusetts General Hospital recently launched CareZone—a mobile clinic aimed at engaging and treating those struggling with opioid use disorder and related health issues.
Relying on qEEG to map the grid of brain waves, physicians can use neurofeedback therapy to train themselves to improve behavioral outcomes, such as sharper focus and reduced distractibility.
Although the causes of MS remain unknown, a variety of factors have been linked to exacerbations and relapse—and several that have recently been associated with increased risk of onset are avoidable.